Nilotinib Treatment in Mouse Models of Lymphoblastic Leukemia
Author Information
Author(s): Kaur Pavinder, Feldhahn Niklas, Zhang Bin, Trageser Daniel, Müschen Markus, Pertz Veerle, Groffen John, Heisterkamp Nora
Primary Institution: Saban Research Institute, Childrens Hospital Los Angeles and the Keck School of Medicine, University of Southern California
Hypothesis
Is nilotinib effective against lymphoblastic leukemia caused by the P190 form of Bcr/Abl?
Conclusion
Nilotinib shows impressive anti-leukemia activity, but resistance can develop through mechanisms that are Bcr/Abl independent.
Supporting Evidence
- Nilotinib-treated mice survived significantly longer than untreated mice.
- Visible lymphoma masses disappeared within six days of treatment.
- Nilotinib was found to be 10-25 times more effective than imatinib.
Takeaway
Nilotinib is a medicine that helps treat a type of blood cancer in mice, but sometimes the cancer can come back even after treatment.
Methodology
Mice were transplanted with leukemic cells and treated with nilotinib to assess its effectiveness in vivo.
Limitations
The study was conducted in mouse models, which may not fully replicate human responses.
Participant Demographics
C57Bl/6J mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website